Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR1 | O14842 | 1/20 | 0.40 |
| ▸ | FGFR1 | P11362 | 14/20 | 0.38 |
| ▸ | FGFR2 | P21802 | 13/20 | 0.38 |
| ▸ | FGFR3 | P22607 | 13/20 | 0.38 |
| ▸ | ACVR1 | Q04771 | 1/20 | 0.38 |
| ▸ | IGF1R | P08069 | 1/20 | 0.37 |
| ▸ | WNT1 | P04628 | 1/20 | 0.34 |
| ▸ | GSK3B | P49841 | 1/20 | 0.34 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.34 |
| ▸ | RET | P07949 | 1/20 | 0.32 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2998098 | 0.86 | FFAR1 (0.41) | FFAR1 | |
| SCHEMBL21292310 | 0.86 | FFAR1 (0.41) | FFAR1WNT1GSK3BDYRK1A | |
| SCHEMBL21626900 | 0.84 | FFAR1 (0.44) | FFAR1FGFR1GSK3BDYRK1A | |
| SCHEMBL26602636 | 0.83 | FFAR1 (0.39) | FFAR1 | |
| SCHEMBL657486 | 0.83 | FFAR1 (0.44) | FFAR1ACVR1WNT1GSK3BDYRK1A | |
| SCHEMBL659001 | 0.82 | FFAR1 (0.39) | FFAR1GSK3BDYRK1A | |
| SCHEMBL1987497 | 0.81 | FFAR1 (0.49) | FFAR1IRAK4 | |
| SCHEMBL25292939 | 0.81 | FFAR1 (0.39) | FFAR1FGFR1FGFR2FGFR3WNT1 | |
| SCHEMBL2322548 | 0.81 | FFAR1 (0.46) | FFAR1FGFR1FGFR2FGFR3WNT1 | |
| SCHEMBL22558769 | 0.80 | FFAR1 (0.40) | FFAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-108349969-B | Substituted pyrazolo [1,5-a ] pyridine compounds as RET kinase inhibitors | 阵列生物制药公司 | 2022-05-10 | — | — | CN | disclosed |
| WO-2019233459-A1 | HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR INHIBITOR, PREPARATION METHOD THEREFOR AND USE THEREOF | 江苏威凯尔医药科技有限公司 (CN) | 2019-12-12 | — | — | WO | disclosed |
| US-8378104-B2 | 7-aminofuropyridine derivatives | OSI Pharmaceuticals, LLC (US) | 2013-02-19 | — | — | US | disclosed |
| EP-2534156-A1 | 7-AMINOFUROPYRIDINE DERIVATIVES | OSI Pharmaceuticals, LLC (US) | 2012-12-19 | — | — | EP | disclosed |
| US-8178668-B2 | 2-aminopyridine kinase inhibitors | OSI Pharmaceuticals, LLC (US) | 2012-05-15 | — | — | US | disclosed |
| US-20120046267-A1 | 7-AMINOFUROPYRIDINE DERIVATIVES | OSI PHARMACEUTICALS, INC. | 2012-02-23 | — | — | US | disclosed |
| WO-2011100502-A1 | 7-AMINOFUROPYRIDINE DERIVATIVES | OSI Pharmaceuticals, LLC (US) | 2011-08-18 | — | — | WO | disclosed |
| EP-2265270-A1 | 2-AMINOPYRIDINE KINASE INHIBITORS | OSI Pharmaceuticals, Inc. (US) | 2010-12-29 | — | — | EP | disclosed |
| WO-2009099982-A1 | 2-AMINOPYRIDINE KINASE INHIBITORS | OSI PHARMACEUTICALS, INC. (US) | 2009-08-13 | — | — | WO | disclosed |
| US-20090197862-A1 | 2-AMINOPYRIDINE KINASE INHIBITORS | OSI PHARMACEUTICALS, INC. | 2009-08-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120046267-A1 | 7-AMINOFUROPYRIDINE DERIVATIVES | MAP3K5, STK17A, MAPKAPK5 | FFAR1 2193/4885FGFR1 369/4885FGFR2 1061/4885 |
| US-20090197862-A1 | 2-AMINOPYRIDINE KINASE INHIBITORS | ERBB2, ABL2, TIE1 | FFAR1 2244/4885FGFR1 15/4885FGFR2 20/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.